Pharmacy Guide

Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.

Pharmacy Guide

Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.

← Back to all medicines

Penicillamine 250 mg film-coated tablets

⚠ This medicine appears to have been discontinued

The electronic medicines compendium (emc) no longer publishes a Summary of Product Characteristics for this product, which usually means it is no longer marketed in the UK. The patient leaflet below is kept for reference, but the product may not be available.

If you were prescribed this medicine, other products containing Penicillamine may still be available. Do not stop your treatment — ask your pharmacist or GP what to use instead.

Active substance: Penicillamine
Source: electronic medicines compendium (emc)
Official leaflet: Read the PIL on emc

What it is and what it is used for

for

Penicillamine belongs to a group of medicines called disease modifying antirheumatic drugs (DMARDS). DMARDS work by reducing the body's immune response and the symptoms of rheumatoid arthritis. Penicillamine helps to relieve the pain and stiffness caused by rheumatoid arthritis. It is used when other medicines for rheumatoid arthritis have not worked. Penicillamine is also a chelating agent. This means that it can bind to certain metals in your body, including lead and copper, to help remove them from your body. Penicillamine is used in adults and children to treat: serious, active rheumatoid arthritis, including Still's disease in children Wilson's disease, a condition where the body cannot get rid of copper properly a kidney problem called cystinuria lead poisoning. Penicillamine is used in adults only to treat: chronic active hepatitis – a type of liver disease. Penicillamine is not a painkiller so you should not expect to feel better straight away. It will be a few weeks before your joints feel less stiff and painful. 2.

What you need to know before you take it

e Penicillamine

Your doctor will ask you to have blood tests to check your blood count and kidney function before you start taking Penicillamine. He or she will test your blood and urine regularly while you are taking Penicillamine. This is so that your doctor can check for any side effects and adjust your dose if necessary.

Do not take Penicillamine:

–

if you are allergic to penicillamine or any of the other ingredients of this medicine (listed in section 6) if you have ever had agranulocytosis (reduction in the number of white blood cells) after taking penicillamine if you have ever had aplastic anaemia (a severe reduction in blood cells which can cause weakness, bruising or make infections more likely) after taking penicillamine if you have ever had lupus erythematosus (LE), an allergic condition which causes skin rashes if you suffer from kidney problems if you have thrombocytopenia (a blood disorder which causes bleeding into your skin, bruising and more bleeding than usual after an injury) after taking penicillamine.

If any of the above applies to you, or if you are not sure, talk to your doctor or pharmacist before you take Penicillamine. Warnings and precautions Talk to your doctor or pharmacist before taking Penicillamine, particularly if any of the following applies to you: if you have ever had side effects with gold or you are currently taking medicines that contain gold if you are receiving concurrently antimalarial drugs such as 4-aminoquinolone drugs like hydroxychloroquine phosphate and chloroquine if you have protein in your urine if you are pregnant, trying to become pregnant or breast-feeding if you have blood in your urine if you have leucopenia (a blood disorder which causes susceptibility to infection) if you are elderly. Your doctor should carry out full blood and urine tests: weekly or fortnightly for the first 8 weeks of treatment, and then monthly whenever your dose of penicillamine is increased. If you are taking Penicillamine for Wilson's disease or for cystinuria, your doctor may carry out these tests at less regular intervals. Your doctor may tell you to stop taking Penicillamine if: your thrombocyte count or your white blood cell count fall below certain levels, or either count falls for three tests in a row. If, after stopping your tablets your blood cell counts return to normal, you may be able to restart treatment at a lower dose. If, after restarting your tablets at a lower dose you develop low blood counts again, you should permanently stop taking this medicine. Other medicines and Penicillamine Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. Penicillamine may increase the risk of side effects if you also take the following medicines:

  • gold (used to treat rheumatoid arthritis)
  • antimalarial drugs such as hydroxychloroquine phosphate, chloroquine (used to treat malaria), as taking together these medicines increase the risk of damaging your kidneys and change in your blood cell counts.
  • NSAIDs (non-steroidal anti-inflammatory drugs) e.g. ibuprofen or naproxen (used to treat arthritis and for pain relief) as there is an increased risk of damaging your kidneys
  • clozapine (used to treat schizophrenia) as taking Penicillamine with clozapine may increase the potential side effects on the bone marrow. The effectiveness of Penicillamine may be altered if you also take the following medicines:

–

iron therapy (used to treat low iron levels or anaemia). Take the iron at least two hours before or after taking Penicillamine antacids (used to neutralise acid in your stomach). Take the antacids at least two hours before or after taking Penicillamine zinc (used to treat low zinc levels), concomitant use may reduce the effect of both medicine.

Penicillamine may affect how well the following medicines work:

  • digoxin (used for an irregular heartbeat). Your doctor may give you pyridoxine (vitamin B6) if you are taking Penicillamine long term, especially if you are on restricted diet. Penicillamine with food and drink Penicillamine should be taken on an empty stomach, and at least half an hour (one hour for children with Wilson's disease or cystinuria) before a meal, with a drink of water. Pregnancy and breast-feeding You should not take Penicillamine if you are pregnant. Penicillamine may reach your baby through the breast milk. Therefore, you should not take Penicillamine if you are breast-feeding. If your doctor considers that treatment is absolutely essential, he may tell you to take Penicillamine even when you are pregnant or breast-feeding. This will depend on your condition and the disease you have. If you are pregnant or breast feeding, think you may be pregnant or are planning to have baby, ask your doctor or pharmacist for advice before taking this medicine. Driving and using machines Penicillamine is not known to affect your ability to drive or use machines. Penicillamine contains lactose and sodium If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine. This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially 'sodiumfree'. 3.

How to take it

penicillamine

Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure. You will have regular blood and urine tests, especially when you start taking the tablets and when you increase the dose. These are to check for changes in your blood cell counts and to look for protein or blood in your urine. The recommended dose for each condition is given below. Use in adults Rheumatoid Arthritis: Take 125 mg to 250 mg per day for the first month. Your doctor will then tell you how to increase the dose gradually over several months until your symptoms get better. Your doctor will monitor you closely until a minimum daily dose is found that controls your symptoms (your maintenance dose).

This may take some months. The usual maintenance dose is 500 mg to 750 mg per day but may be as high as 1500 mg per day. It may be several months before you feel better. If there is no improvement after taking the tablets for 1 year, your doctor will tell you to stop taking the tablets. If your symptoms are controlled continuously for 6 months, your doctor may reduce your daily dose. Wilson's disease: The recommended dose is between 1500 mg to 2000 mg per day in divided doses. If your symptoms are controlled, your doctor may reduce your dose. You should not take a dose of 2000 mg or more per day for more than 12 months. Cystinuria: Your doctor will take a sample to measure the amount of cystine (an amino acid) in your urine. From this he will be able to work out the lowest dose that will still be effective for you. Prevention of cystine stones: 500 mg to 1000 mg at bedtime. It is important that you drink enough fluids (not less than 3 litres per day). Dissolving cystine stones: 1000 mg to 3000 mg per day, in divided doses. Lead Poisoning: 1000 mg to 1500 mg per day, in divided doses until your doctor tells you that the amount of lead in your urine is normal. Active Chronic Hepatitis: Your doctor should take a blood sample regularly to check that your liver is working well. For maintenance, initially 500 mg per day in divided doses, increasing over 3 months to a maintenance dose of 1250 mg per day. Use in elderly Rheumatoid Arthritis: The recommended dose is 125 mg daily for the first month. Your doctor will then tell you how to increase the dose gradually over several months until you are feeling better. You should not take more than 1000 mg daily. It may be several months before you feel better. If there is no improvement after taking the tablets for 1 year, your doctor will tell you to stop taking the tablets. If you stay well for six months your doctor may reduce your dose. Wilson's disease: Your dose will depend on your weight. The recommended dose is 20 mg a day for each kilogram of body weight in divided doses. Your doctor will reduce the dose over time to find the minimum necessary to control your disease. Cystinuria: Your doctor will determine your dose. Lead poisoning: Your dose will depend on your weight. The recommended dose is 20 mg a day for each kilogram of body weight in divided doses, until your doctor tells you the amount of lead in your blood is normal. Active Chronic Hepatitis: Penicillamine is not recommended for the treatment of active chronic hepatitis in the elderly.

Use in children The dose may depend on the weight of the child. As the smallest available tablet is 125 mg, it might be too large for very small children. Rheumatoid arthritis: The recommended dose is 15 mg to 20 mg a day for each kilogram of body weight. You will start with a low dose for the first month and increase gradually. Wilson's disease: For children under 12 years, 20 mg a day for each kilogram of body weight in two or three separate doses given 1 hour before meals. For older children the usual dose is 750 mg to 1000 mg daily. Cystinuria: The recommended starting dose is 20 mg to 30 mg for each kilogram of body weight, in two or three separate doses given 1 hour before meals. Your doctor may change your dose depending on the results of the tests on your urine. Lead poisoning: The recommended dose is 15 mg to 20 mg a day for each kilogram of body weight, in two or three separate doses. Active Chronic Hepatitis: Penicillamine is not recommended for the treatment of active chronic hepatitis in the paediatric population. If you have kidney problems your doctor will start you on a lower dose. Method of administration When taking Penicillamine:

  • swallow the tablets with water
  • always take your tablets at least half an hour (or 1 hour for children) before a meal, or at bedtime
  • if you are taking iron tablets, antacids or digoxin take them at least two hours before or after you have taken penicillamine
  • take your tablets as long as your doctor tells you to
  • do not take more tablets than your doctor tells you to. If you take more Penicillamine than you should If you accidentally take too many tablets, contact your doctor or nearest hospital emergency department immediately for advice. If you forget to take Penicillamine Unless it is almost time for the next dose, take it as soon as you remember, then just carry on as before. Do not take a double dose to make up for a forgotten tablet. If you stop taking Penicillamine Do not stop or change your treatment before talking to your doctor. If you have any further questions on the use of this medicine, ask your doctor or pharmacist. 4.

Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them. Contact your doctor or go to your nearest hospital emergency department immediately if you think you may have any of the following serious side effects: Common: may affect up to 1 in 10 people

  • bruising more easily, nose bleeds and/or bleeding gums more often. These may be signs of a blood disorder called thrombocytopenia. Rare: may affect up to 1 in 1,000 people
  • allergic reactions which includes sudden wheeziness, chest pain, difficulty in breathing, sudden swelling, fever, skin rash or itching
  • blood in your urine. Not known: frequency cannot be estimated from the available data
  • blood reactions that may cause unusual bleeding or bruising of the skin, may reduction of the number of white cells in your blood, causing more infections than usual
  • fever, severe chills, sore throat or mouth ulcer, feeling of extreme tiredness or weakness, paleness of the skin and more susceptible to infections. These may be signs of anaemia
  • breakdown of the tissues of your kidney (nephrotic syndrome)
  • blistering skin rash or severe skin reactions, blistering of the skin, mouth, throat, nose, eyes and genitals (Stevens-Johnson syndrome or pemphigus)
  • damage to your kidneys and bleeding in your lungs caused by your body's immune system (Goodpasture's syndrome)
  • coughing up blood (pulmonary haemorrhage)
  • inflammation of the pancreas with severe upper stomach pain, feeling and being sick (pancreatitis)
  • vasculitis. Other side effects that can occur: Very common: may affect more than 1 in 10 people
  • protein in your urine (this is detected by a urine test). Rare: may affect up to 1 in 1,000 people
  • sore mouth, mouth ulcer
  • swollen breast tissue
  • hair loss
  • wrinkly skin
  • abnormalities of the elastic fibres in the skin which cause clusters of the small reddish bumps usually on the neck or arms. Not known: frequency cannot be estimated from the available data
  • loss of taste
  • feeling sick (especially at the start of treatment) or being sick
  • loss of appetite (especially at the start of treatment)
  • jaundice (yellowing of the skin or eyes) as a result of liver or blood problems (this may include changes in blood test which show how your liver is working)
  • lung problems (e.g. wheezing, coughing or difficulty in breathing)
  • a condition that causes nails to become thicker and yellow or greenish-yellow in colour, chronic swelling in the limbs (hand and feet) and chronic breathing problem
  • redness, a rash or itching (especially at the start of treatment)
  • fever (especially at the start of treatment) or frequent infections
  • muscle weakness and tiredness (sometimes with skin rashes)

• • •

worsening of the pain and swelling in your joints lupus erythmatosus (an allergic condition which causes joint pain, skin rashes and fever) newly diagnosed rheumatoid arthritis.

After several months or years of therapy you may develop a particular rash that makes your skin fragile called acquired epidermolysis bullosa or penicillamine dermopathy. If you get this your doctor may tell you to take a lower dose. If you suffer from rheumatoid arthritis you should tell your doctor if your joints become more painful, swollen, red or hot because medicines like Penicillamine sometimes cause joint infections. If you suffer from Wilson's disease you should tell your doctor if you experience:

  • a worsening of muscle spasms
  • muscle stiffness
  • tremor or slurred speech. Reporting of side effects If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard. By reporting side effects you can help provide more information on the safety of this medicine. 5.

How to store it

Penicillamine

Keep this medicine out of the sight and reach of children. Store your tablets in a cool, dry place below 25°C. Do not use this medicine after the expiry date which is stated on the bottle after 'EXP'. The expiry date refers to the last day of that month. Do not throw any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help to protect the environment. 6.

Contents of the pack and other information

What Penicillamine film-coated tablets contain The active substance is penicillamine. Each 125 mg tablet contains 125 mg penicillamine. Each 250 mg tablet contains 250 mg penicillamine. The other ingredients are: povidone, lactose, sodium starch glycollate, magnesium stearate. The film-coat contains: hydroxypropyl, methylcellulose (E464), titanium dioxide (E171), polyethylene glycol, carnauba wax. What Penicillamine looks like and contents of the pack Your medicine comes as a round, white film coated tablet. On one side, the 125 mg tablet is embossed with 'PC 125' and marked 'G' on the reverse, the 250 mg is embossed with 'PC 250' on one side and marked 'G' on the reverse. Penicillamine film-coated tablets are available in polypropylene containers with polyethylene caps in packs of 5, 7, 10, 14, 15, 20, 21, 25, 28, 30, 56, 60, 84, 90, 100, 112, 120, 168, 180, 250 and 1000 tablets. Not all pack sizes may be marketed.

Marketing Authorisation Holder Mylan, Potters Bar, Herts, EN6 1TL, United Kingdom. Manufacturer Gerard Laboratories, 35/36 Baldoyle Industrial Estate, Grange Road, Dublin 13, Ireland. Mylan Hungary Kft, Mylan utca 1, Komȃrom, 2900, Hungary This leaflet was last revised in 05/2026.

Frequently asked questions about Penicillamine 250 mg film-coated tablets

How do I take Penicillamine 250 mg film-coated tablets?

Penicillamine 250 mg film-coated tablets comes as tablet containing 250mg. Always follow the dose your doctor or pharmacist has given you, and read the leaflet that comes with the medicine.

What is the active substance in Penicillamine 250 mg film-coated tablets?

The active substance in Penicillamine 250 mg film-coated tablets is penicillamine.

Where does this information come from?

This leaflet reproduces the patient information leaflet approved for Penicillamine 250 mg film-coated tablets, as published on the electronic medicines compendium (emc). The version printed inside your medicine’s packaging is the one that applies to you.

Can I get Penicillamine 250 mg film-coated tablets without a prescription?

Whether a medicine is available over the counter or on prescription only depends on its licence. Check the leaflet, or ask your pharmacist — they can tell you straight away.

About this leaflet

The text above reproduces the patient information leaflet approved for this medicine, restructured for easier reading.

Medical disclaimer: This page is for information only and does not replace advice from your doctor or pharmacist. Always read the leaflet supplied with your medicine. If you are unwell, call NHS 111; in an emergency, call 999.

Medicines with the same active substance: Penicillamine (2 medicines)
See every medicine containing this substance, or browse the full A–Z of active substances.
⚕For healthcare professionals — Summary of Product Characteristics (SmPC)Full SmPC: dosage, interactions, contraindications, warnings+
Technical information intended for healthcare professionals (doctors and pharmacists). The Summary of Product Characteristics (SmPC) is the official document approved by the MHRA/EMA. It does not replace the patient leaflet or a doctor’s advice.

4.1. Therapeutic indications

1. Severe active rheumatoid arthritis including juvenile forms.

2. Wilson's disease (hepatolenticular degeneration) in adults and children (0 to 18 years).

3. Cystinuria – dissolution and prevention of cystine stones in adults and children (0 to 18 years).

4. Lead poisoning in adults and children (0 to 18 years).

5. Chronic active hepatitis in adults.

4.2. Posology and method of administration

Posology

a) Rheumatoid Arthritis

Adults

A daily dose of 125 - 250 mg per day is recommended for the first month, increasing by the same amount every four to twelve weeks until remission occurs. The minimum maintenance dose to achieve suppression of symptoms should be used and treatment should be discontinued if no improvement occurs within 12 months. Improvement may not occur for some months. The usual maintenance dose is 500 mg to 750 mg daily. However, up to 1500 mg daily may be required.

Reduction in maintenance dosage by 125 mg to 250 mg every 12 weeks may be attempted after a period of 6 months continuous remission.

Elderly

The initial dose should not exceed 125 mg daily for the first month, increasing by similar increments every four to twelve weeks until the minimum maintenance dose to supress symptoms is reached. Daily dosage should not exceed 1000 mg (see section 4.4).

Paediatric population

The usual maintenance dose is 15 to 20 mg/kg/day. The initial dose should be lower (2.5 to 5 mg/kg/day) and increased every four weeks over a period of three to six months.

Patients with Renal impairment

Penicillamine therapy should be initiated at a low dose with intervals between dose increase of at least twelve weeks. Fortnightly monitoring for toxicity is mandatory throughout treatment for rheumatoid arthritis.

b) Wilsons Disease

Patients must be maintained in negative copper balance and the minimum dose of Penicillamine required to achieve this should be given.

Adults

1500 mg to 2000 mg daily in divided doses. Dose reduction may be attempted when remission occurs, decreasing to 750 mg to 1000 mg per day. It is advisable that a dose of 2000 mg per day should not be continued for more than 12 months.

Elderly

20 mg/kg/day in divided doses adjusting the dose minimal level necessary to control disease.

Paediatric population

20 mg/kg/day in two or three divided doses, given 1 hour before meals. For older children (>12 years) the usual maintenance dose is 750 mg to 1000 mg daily.

Patients with Renal impairment

Extra precautions should be taken to monitor for adverse effects in patients with Wilson's disease and renal insufficiency.

c) Cystinuria

The lowest effective dose should be used and this is determined by quantitative amino acid chromatography of urine.

(i) Dissolution of cystine stones

Adults

1000 mg to 3000 mg daily, in divided doses. Cystine levels in urine should not exceed 200 mg/litre.

(ii) Prevention of cystine stones

Adults

500 mg to 1000 mg at bedtime. Maintenance of adequate fluid intake (not less than 3 litres/day is important). Cystine levels in the urine should not exceed 300 mg/litre.

Elderly

Use the minimum dose to maintain urinary cystine levels below 200 mg/litre.

Paediatric population

20 to 30 mg/kg/day in two or three divided doses, given 1 hour prior to meals, adjusted to maintain urinary cystine level below 200 mg/litre.

Patients with Renal impairment

If renal insufficiency is present at the onset of therapy, the starting dose should be lower, but it will be necessary to give sufficient Penicillamine to achieve urine cystine levels of not more than 300 mg/litre. The maintenance dose should be reviewed at intervals of not more than four weeks.

d) Lead Poisoning

Adults

1000 mg to 1500 mg daily, in divided doses until urinary lead is stabilised at less than 0.5 mg per day.

Elderly

20 mg/kg/day in divided doses until lead levels in the urine is stabilised at less than 0.5 mg per day.

Paediatric population

Penicillamine should only be used in cases where blood lead levels <45 mcg/dL. A total of 15 – 20 mg/kg/day in 2 – 3 doses should be used.

e) Chronic active hepatitis

Adults

For maintenance treatment after the disease process has been brought under control with corticosteroids. The initial dose of 500 mg daily in divided doses, should be increased gradually over three months to a maintenance dose of 1250 mg daily. During this period, the dose of corticosteroids should be phased out. Throughout therapy, liver function tests should be carried out periodically to assess the disease status.

Elderly

Not recommended.

Paediatric population

The safety and efficacy of penicillamine in children less than 18 years with chronic active hepatitis has not been established. No data are available.

Method of administration

For oral administration.

Penicillamine should be taken on an empty stomach at least half an hour before meals in adults and one hour before meals in paediatric patients, or on retiring.

As the smallest available tablet is 125 mg, this might not be suitable for very young children.

4.3. Contraindications

Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

Agranulocytosis, aplastic anaemia or severe thrombocytopenia due to penicillamine.

Lupus erythematosus.

Moderate or severe renal impairment.

4.4. Special warnings and precautions for use

Full blood and platelet counts should be performed and renal function should be assessed prior to treatment with penicillamine.

Monitoring of blood and platelet counts should be carried out at appropriate intervals, together with urinalysis for detection of haematuria and proteinuria (see section 4.8). Urinalysis should be carried out weekly at first, and following each increase in dose, then monthly, although longer intervals may be adequate for cystinuria and Wilson's disease. Increasing or persistent proteinuria may necessitate withdrawal of therapy.

During the first eight weeks of therapy full blood counts should be carried out weekly or fortnightly and also in the week after any increase in dose, otherwise monthly thereafter. In cystinuria or Wilson's disease, longer intervals may be adequate.

If platelets fall below 120,000 per mm3 or white blood cells below 2,500 per mm3, or if three consecutive falls are noted within the normal range, withdrawal of treatment should be considered. When counts return to normal, treatment may be restarted at a reduced dosage, but should be permanently withdrawn on recurrence of leucopenia or thrombocytopenia. Penicillamine may potentiate the bone marrow suppression caused by clozapine.

Care should be taken and dosage modified, if needed, in patients with renal impairment (see section 4.2).

Especially careful monitoring is necessary in older people since increased toxicity has been observed in this patient population regardless of renal function.

Concomitant use of NSAIDs and other nephrotoxic drugs may increase the risk of renal damage (see section 4.5).

Penicillamine should be used with caution in patients who have had adverse reactions to gold.

Concomitant or previous treatment with gold may increase the risk of side effects with penicillamine treatment. Therefore penicillamine should be used with caution in patients who have previously had adverse reactions to gold and concomitant treatment with gold should be avoided (see section 4.5).

Penicillamine should not be used in patients who are receiving concurrently antimalarial drugs such as hydroxychloroquine phosphate, chloroquine. These drugs having similar hematologic and renal adverse reactions, could act synergistically when used together with penicillamine (See section 4.5).

If concomitant oral iron, digoxin or antacid therapy is indicated, this should not be given within two hours of taking penicillamine (see section 4.5).

Antihistamines, steroid cover, or temporary reduction of dose will control urticarial reactions (see section 4.8).

Reversible loss of taste may occur. Mineral supplements to overcome this are not recommended (see section 4.8).

Haematuria is rare, but if it occurs in the absence of renal stones or other known causes, treatment should be stopped immediately (see section 4.8).

A late rash, described as acquired epidermolysis bullosa and penicillamine dermopathy, may occur after several months or years of therapy. This may necessitate a reduction in dosage (see section 4.8).

Breast enlargement has been reported as a rare complication of penicillamine therapy in both women and men (see section 4.8). Danazol has been used successfully to treat breast enlargement which does not regress on drug discontinuation.

The use of DMARDs, including penicillamine, has been linked to the development of septic arthritis in patients with rheumatoid arthritis, although rheumatoid arthritis is a stronger predictor for the development of septic arthritis than the use of a DMARD (see section 4.8).

Deterioration of the neurological symptoms of Wilson's disease (dystonia, rigidity, tremor, dysarthria) have been reported following introduction of penicillamine in patients treated for this condition. This may be a consequence of mobilisation and redistribution of copper from the liver to the brain (see section 4.8).

Pyridoxine daily may be given to patients on long term therapy, especially if they are on a restricted diet, since penicillamine increases the requirement of this vitamin (see section 4.5).

These tablets contain lactose. Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should not take this medicine.

This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially 'sodium-free'.

4.5. Interaction with other medicinal products and other forms of interaction

Concomitant use of iron or antacids: oral absorption of penicillamine may be reduced by concomitant administration of iron or antacid (see section 4.4).

Concomitant use of digoxin: oral absorption of digoxin may be reduced by concomitant administration of penicillamine (see section 4.4).

Concomitant use of NSAIDs and other nephrotoxic drugs may increase the risk of renal damage (see section 4.4).

Concomitant use of antimalarial drugs such as hydroxychloroquine phosphate, chloroquine: These drugs having similar hematologic and renal adverse reactions, could act synergistically when used together with penicillamine. (see section 4.4).

Concomitant use of gold: concomitant use is not recommended (see section 4.4).

Concomitant use of clozapine: penicillamine may potentiate the blood dyscrasias seen with clozapine (see section 4.4).

Concomitant use of zinc: oral absorption of penicillamine may be reduced by concomitant administration of zinc; absorption of zinc may also be reduced by penicillamine.

Pyridoxine daily may be given to patients on long term therapy, especially if they are on a restricted diet, since penicillamine increases the requirement for this vitamin (see section 4.4).

4.6. Fertility, pregnancy and lactation

Pregnancy

The safety of penicillamine for use during pregnancy has not been established (see section 5.3).

Wilson's disease: There have been several cases of reversible cutis laxa in infants born to mothers taking penicillamine throughout pregnancy. Although there have been no controlled studies on the use of penicillamine during pregnancy, two retrospective studies have reported the successful delivery of 43 normal infants to 28 women receiving between 500 mg and 2000 mg of penicillamine daily. There are also anecdotal reports both of congenital abnormalities and of successful outcomes in patients who have remained on penicillamine during pregnancy. If treatment with penicillamine is to be continued following a risk-benefit analysis, consideration should be given to reducing the dose of penicillamine to the lowest effective dose.

Cystinuria: Whilst normal infants have been delivered, there is one report of a severe connective tissue abnormality in the infant of a mother who received 2000 mg penicillamine daily throughout pregnancy. Whenever possible, penicillamine should be withheld during pregnancy, but if stones continue to form, the benefit of resuming treatment must be weighed against the possible risk to the foetus.

Rheumatoid arthritis or chronic active hepatitis: Penicillamine should not be administered to patients who are pregnant, and therapy should be stopped when pregnancy is diagnosed or suspected, unless considered to be absolutely essential by the physician.

Breast-feeding

Due to the lack of data on the use in breast-feeding patients and the possibility that penicillamine may be transmitted to newborns through breast milk, penicillamine should only be used in breast-feeding patients when it is considered absolutely essential by the physician.

4.7. Effects on ability to drive and use machines

None known.

4.8. Undesirable effects

The most common of all side-effects are thrombocytopenia and proteinuria.

Thrombocytopenia occurs commonly. The reaction may occur at any time during treatment and is usually reversible.

Proteinuria occurs in up to 30% of patients and is partially dose-related (see section 4.4).

Adverse reactions are ranked under the heading of frequency, the most frequent first, using the following convention: very common (≥ 1/10), common (≥ 1/100, < 1/10), uncommon (≥ 1/1000, < 1/100), rare (≥ 1/10,000, < 1/1000), very rare (< 1/10,000) and not known (frequency cannot be estimated from the available data).

The incidence and severity of some of the adverse reactions, noted below, varies according to the dosage and nature of the disease under treatment.

Blood and lymphatic system disorders

Common:

Not known:

Thrombocytopenia.

Neutropenia 8, agranulocytosis 1, aplastic anaemia 1, haemolytic anaemia, leucopenia.

Immune system disorders

Rare:

Allergic reactions including hypersensitivity.

Metabolism and nutrition disorders

Not known:

Anorexia 2.

Nervous system disorders

Not known:

Loss of taste 4.

Vascular disorders

Not known:

Pulmonary haemorrhage, vasculitis.

Respiratory, thoracic and mediastinal disorders

Not known:

Inflammatory conditions of the respiratory tract such as bronchiolitis, pneumonitis, yellow nail syndrome.

Gastrointestinal disorders

Rare:

Not known:

Mouth ulceration, stomatitis.

Pancreatitis, nausea 2, vomiting.

Hepatobiliary disorders

Not known:

Cholestatic jaundice.

Skin and subcutaneous tissue disorders

Rare:

Not known:

Alopecia, pseudoxanthoma elasticum, elastosis perforans, skin laxity.

Rashes 2, urticarial reactions 3, dermatomyositis, pemphigus, Stevens-Johnson syndrome, acquired epidermolysis bullosa 6, penicillamine dermopathy 6.

Musculoskeletal and connective tissue disorders

Not known:

Drug induced lupus erythematosus, myasthenia gravis, polymyositis, rheumatoid arthritis.

Renal and urinary disorders

Very common:

Rare:

Not known:

Proteinuria.

Haematuria 5.

Nephrotic syndrome, glomerulonephritis, Goodpasture's syndrome.

Reproductive system and breast disorders

Rare:

Breast enlargement 7.

General disorders and administration site conditions

Not known:

Fever 2.

1. Deaths from agranulocytosis and aplastic anaemia have occurred.

2. Nausea, anorexia, fever and rash may occur early in therapy, especially when full doses are given from the start.

3. Antihistamines, steroid cover, or temporary reduction of dose will control urticarial reactions (see section 4.4).

4. Reversible loss of taste may occur. Mineral supplements to overcome this are not recommended (see section 4.4).

5. Haematuria is rare, but if it occurs in the absence of renal stones or other known cause, treatment should be stopped immediately (see section 4.4).

6. A late rash, described as acquired epidermolysis bullosa and penicillamine dermopathy, may occur after several months or years of therapy (see section 4.4).

7. Breast enlargement has been reported as a rare complication of penicillamine therapy in both women and men (see section 4.4).

8. The reaction may occur at any time during treatment and are usually reversible (see section 4.4).

The development of septic arthritis in patients with rheumatoid arthritis has been linked to the use of DMARDs, including penicillamine (see section 4.4).

Deterioration of the neurological symptoms of Wilson's disease (dystonia, rigidity, tremor, dysarthria) have been reported following the introduction of penicillamine in patients treated for this condition (see section 4.4).

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard.

4.9. Overdose

There are no reported cases of undesirable reactions to penicillamine overdosage and no special treatment is recommended.

🇷🇴 Known in Romania as

Medicines sold in Romania with the same active substance: Cunoscut în România ca

  • CUPRIPEN 250 mg prescriptionPENICILLAMINUM · taken by mouth
  • CUPROS L 250 mg prescriptionPENICILLAMINUM · taken by mouth

Same active substance. The strength, the form and whether you need a prescription can differ. Always ask a pharmacist before you switch. Romanian medicines in the UK →

🇵🇱 Known in Poland as

Medicines sold in Poland with the same active substance: W Polsce znany jako

  • CuprenilPenicillaminum · taken by mouth

Same active substance. The strength, the form and whether you need a prescription can differ. Always ask a pharmacist before you switch. Polish medicines in the UK →

💬 Ask about this leaflet

Ask anything about Penicillamine 250 mg film-coated tablets. The assistant answers only from this leaflet — if the leaflet does not cover it, it will say so. It does not give medical advice.

Answers come from the patient leaflet published on the electronic medicines compendium (emc). They are not medical advice. Ask a pharmacist or your GP if you are unsure. For urgent help call NHS 111, or 999 in an emergency.

Medicines containing Penicillamine

Pharmacies in major towns and cities — see the list
Pharmacies by county and region — see the full list

Browse all 2,009 towns and cities →